RT Journal Article
SR Electronic
T1 Implementation of SARS-CoV2 Screening in K-12 Schools using In-School Pooled Molecular Testing and Deconvolution by Rapid Antigen Test
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.03.21256560
DO 10.1101/2021.05.03.21256560
A1 Nira R. Pollock
A1 David Berlin
A1 Sandra C. Smole
A1 Lawrence C. Madoff
A1 Kelsey Henderson
A1 Elizabeth Larsen
A1 Jeremiah Hay
A1 Stacey Gabriel
A1 Atul A. Gawande
A1 Niall J. Lennon
YR 2021
UL http://medrxiv.org/content/early/2021/05/05/2021.05.03.21256560.abstract
AB What is already known about this topic?SARS-CoV2 testing is a key component of a multi-layered mitigation strategy to enable safe return to in-person school for the K-12 population. However, costs, logistics, and uncertainty about effectiveness are potential barriers to implementation.What is added by this report?Over three months, 259,726 individual swabs were tested across 50,636 pools from 582 schools. Pool positivity rate was 0.8%; 98.1% of pools tested negative and 0.3% inconclusive, and 0.8% of pools submitted could not be tested. In reflex testing, 92.5% of fully deconvoluted pools with N1 or N2 target Ct ≤30 yielded a positive individual using the BinaxNOW antigen rapid diagnostic test (Ag RDT) performed 1-3 days later. With sufficient staffing support and low pool positivity rates, pooled sample collection and reflex testing were feasible for schools.What are the implications for public health practice?Screening testing for K-12 students and staff is achievable at scale and at low cost with a scheme that incorporates in-school pooling, RT-PCR primary testing, and Ag RDT reflex/deconvolution testing. Staffing support is a key factor for program success.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project was supported by the Centers for Disease Control and Prevention Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020 within Project E: Emerging Infections ELC Reopening Schools (Grant #6 NU50CK000518-02-06) of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award totaling $205M. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, CDC/HHS or the U.S. Government. The work at the Broad Institute was funded, in part, by the NIBIB RADx Advanced Technology Program and the Commonwealth of Massachusetts. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Massachusetts Department of Public Health IRB reviewed and approved the work (and considered it not human subjects research).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe work here represents summary data from the implementation of testing. No individual level patient data is made available as part of this work.